Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics

Journal of Alzheimer's Disease

Volumn 52, Issue 1, 2016, Pages 51-64

  Lelental, Natalia ^a   Brandner, Sebastian ^a   Kofanova, Olga ^b   Blennow, Kaj ^c   Zetterberg, Henrik ^c,d   Andreasson, Ulf ^c   Engelborghs, Sebastiaan ^e,ae   Mroczko, Barbara ^f   Gabryelewicz, Tomasz ^g   Teunissen, Charlotte ^h   Mollenhauer, Brit ⁱ   Parnetti, Lucilla ^j   Chiasserini, Davide ^j   Molinuevo, Jose Luis ^k   Perret Liaudet, Armand ^l   Verbeek, Marcel M ^m   Andreasen, Niels ⁿ   Brosseron, Frederic ^o   Bahl, Justyna M C ^p   Herukka, Sanna Kaisa ^q   Hausner, Lucrezia ^r   Frölich, Lutz ^r   Labonte, Anne ^s   Poirier, Judes ^s   Miller, Anne Marie ^t   Zilka, Norbert ^u   Kovacech, Branislav ^u   Urbani, Andrea ^v,af   Suardi, Silvia ^w   Oliveira, Catarina ^x   Baldeiras, Ines ^x   Dubois, Bruno ^y   Rot, Uros ^z   Lehmann, Sylvain ^aa   Skinningsrud, Anders ^ab   Betsou, Fay ^b   Wiltfang, Jens ⁱ   Gkatzima, Olymbia ^ac   Winblad, Bengt ^ad   Buchfelder, Michael ^a   Kornhuber, Johannes ^a   Lewczuk, Piotr ^a,f   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b INTEGRATED BIOBANK OF LUXEMBOURG   (Luxembourg)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j UNIVERSITY OF PERUGIA   (Italy)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPICES CIVILS DE LYON   (France)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY HOSPITAL BONN   (Germany)

^p STATENS SERUM INSTITUT   (Denmark)

^q KUOPIO UNIVERSITY HOSPITAL   (Finland)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^t TRINITY COLLEGE DUBLIN   (Ireland)

^u INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^v IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^w DEPARTMENT OF NEUROSURGERY   (Italy)

^x UNIVERSITY OF COIMBRA   (Portugal)

^y INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^z UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^aa MONTPELLIER UNIVERSITY HOSPITAL   (France)

^ab AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^ac ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^ad KAROLINSKA INSTITUTE   (Sweden)

^ae Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

^af UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

Alzheimer's disease; amyloid ; biomarkers; cerebrospinal fluid; laboratory diagnostics; quality control; tau

Indexed keywords

AMYLOID BETA PROTEIN; BOVINE SERUM ALBUMIN; PHOSPHATE BUFFERED SALINE; SODIUM AZIDE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

ARTICLE; CEREBROSPINAL FLUID; CHEMOLUMINESCENCE; CONTROLLED STUDY; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE DRYING; NEUROCHEMICAL DEMENTIA DIAGNOSTICS; PRIORITY JOURNAL; QUALITY CONTROL; ROOM TEMPERATURE; ANIMAL; BLOOD; BOVINE; CLINICAL CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; MULTICENTER STUDY; PROCEDURES; STANDARD; STANDARDS; TIME FACTOR; TISSUE PRESERVATION; VALIDATION STUDY;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BIOMARKERS; CATTLE; CLINICAL CHEMISTRY TESTS; DEMENTIA; HUMANS; PEPTIDE FRAGMENTS; QUALITY CONTROL; REFERENCE STANDARDS; SERUM ALBUMIN, BOVINE; SODIUM AZIDE; TAU PROTEINS; TIME FACTORS; TISSUE PRESERVATION;

EID: 84973131635     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150883     Document Type: Article

References (23)

1. Lewczuk P, Mroczko B, Fagan A, Kornhuber J (2015) Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective. Adv Med Sci 60, 76-82
2. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69
3. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234
4. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
5. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11, 41-55
6. EMA (2011) Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebrospinal fluid related biomarkers for drugs affecting amyloid burden (EMA/CHMP/SAWP/102001/2011)
7. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schonknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Würster U, Bibl M, Maler JM, Reubach U, Kornhuber J,Wiltfang J (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409, 1-4
8. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395 e386
9. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, PhelpsCH(2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Associationworkgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262
10. Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, Gobom J, Zetterberg H, Kobold U, Portelius E, Blennow K, Scientific Division Working Group on IFCC, CSF, proteins (2014) Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 60, 987-994
11. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P (2011) Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 25, 739-745
12. Lewczuk P (2015) Schlussbericht des Projektes Optimierung der Qualitätskontrolle und Interpretation der Neurochemischen Demenzdiagnostik: Teilprojekt von "Biomarkers for Alzheimer's disease and Parkinson's disease, BIOMARKAPD
13. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. (1998)
14. Reiber H (1994) Flow rate of cerebrospinal fluid (CSF)-A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 122, 189-203
15. Linsinger TPJ, Pauwels J, Veen AMH, Schimmel H, Lamberty A (2001) Homogeneity and stability of reference materials. Accreditation Qual Assur 6, 20-25
16. Lamberty A, Schimmel H, Pauwels J (1998) The study of the stability of reference materials by isochronous measurements. Fresenius J Anal Chem 360, 359-361
17. Auclair G, Zegers I, Charoud-Got J, Munoz Pineiro A, Hanisch K, Boulo S, Trapmamm S, Schimmel H, Emons H, Schreiber W (2011) The certification of the mass concentration of C-Reactive Protein in human serum-Certified Reference Material ERM-DA474/IFCC, Publication Office of the European Union, Luxembourg
18. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amyloid (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem 51, 189-195
19. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-A42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379
20. Fronek K, Lange P, Spreer A, Eiffert H, Nau R (2011) Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of beta-Amyloid and Tau protein as determined by enzyme immunoassay. Dement Geriatr Cogn Disord 32, 126-134
21. Pauwels J, Lamberty A, Schimmel H (1998) Quantification of the expected shelf-life of certified reference materials. Fresenius J Anal Chem 361, 395-399
22. Lewczuk P, Kornhuber J, Wiltfang J (2006) The German Competence Net Dementias: Standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm 113, 1075-1080
23. Betsou F, Sobel ME (2013) The ISBER Biorepository proficiency testing program: Two successful years already, and new features to come. Biopreserv Biobank 11, 255-256